Learning from structure-based drug design and new antivirals targeting the ribonucleoprotein complex for the treatment of influenza.

@article{Monod2015LearningFS,
  title={Learning from structure-based drug design and new antivirals targeting the ribonucleoprotein complex for the treatment of influenza.},
  author={Alexandre Monod and Christopher Swale and Bogdan Tarus and Alice Tissot and Bernard Delmas and Rob W H Ruigrok and Thibaut Cr{\'e}pin and Anny Slama-Schwok},
  journal={Expert opinion on drug discovery},
  year={2015},
  volume={10 4},
  pages={345-71}
}
INTRODUCTION Influenza viruses are a threat to human health. There are presently only two methods for treating influenza: vaccines, which require yearly updates, and two classes of antivirals that suffer with the problem of resistance by current human influenza viruses; this is especially the case with amantadine and rimantadine. Consequently, there is an urgent need for the development of new antivirals with new mechanisms of action. AREAS COVERED In this review, the authors focus on viral… CONTINUE READING